NKNed Kinnear

Ned Kinnear

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ned Kinnear has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bacillus Calmette-Guérin therapy in the management of upper tract urothelial carcinoma in-situ: a systematic review

    by Youssef Garras, Daniah Alsaadi, Ned Kinnear, Derek Hennessey

    Background: Upper urinary tract carcinoma in-situ (UUT-CIS) is an aggressive disease traditionally managed with radical nephroureterectomy (RNU), often resulting in loss of renal function. Topical Bacillus Calmette-Guérin (BCG) therapy has been explored as a kidney-sparing alternative, although evidence remains limited and heterogeneous. This review aimed to synthesise oncological and safety outcomes of topical BCG therapy for UUT-CIS. Methods: A systematic search of PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and grey literature (registration No. CRD420261277998). Eligible studies were published 01/01/2000–14/09/25, enrolled adult patients with UUT-CIS treated with topical BCG and reported oncological or toxicity outcomes. Primary outcomes were rates of complete response, recurrence and progression. Where methodological homogeneity permitted, meta-analysis was planned. Risk of bias was assessed using Risk Of Bias In Non-randomised Studies of Interventions (ROBINS)-I V2. Results: Fourteen observational studies comprising 298 renal units (267 patients) were included (weighted mean age of 71.8 years; 19.2% female). Complete response rates following BCG induction ranged 59–100% per renal unit. Recurrence rates after initial response ranged 0–70% and progression rates ranged 0–43%. The proportion of renal units requiring salvage RNU ranged 0–25%. Renal unit preservation ranged 45–100%. Median follow-up varied substantially at 13–88 months. Adverse events were predominantly local and self-limited; severe systemic toxicity was uncommon, and treatment-related mortality was reported in one patient. Substantial heterogeneity existed in follow-up duration, delivery technique, surveillance protocols, and outcome definitions, negating meta-analysis. Most included studies demonstrated a moderate risk of bias across key ROBINS-I domains, reflecting observational study design and the absence of randomized trials. Conclusions: Topical BCG therapy for UUT-CIS is associated with high initial response rates and meaningful renal preservation and may represent a kidney-sparing option in carefully selected or imperative clinical scenarios. However, recurrence and progression rates remain variable. Topical BCG therapy should not be considered equivalent to RNU, which remains the oncological standard of care.


  • Safety and Efficacy of Intravesical Gentamicin for Recurrent Urinary Tract Infections and/or Catheter Blockages

    by Ned Kinnear, Lance Coleman, Kara Parsons, Leigh Casey, Richard Baverstock

    Aims: To assess the safety and efficacy of intravesical gentamicin in patients with recurrent urinary tract infections (UTI) and/or catheter blockages. Methods: This prospective, single‐center study enrolled adult patients with recurrent UTIs and/or catheter blockages who had been prescribed intravesical gentamicin (once‐daily, 30−60 mL, 0.48 mg/mL, held 60 min) from June 1, 2024, to April 1, 2025. Eligible patients had received ≥ 14 days' intravesical gentamicin. Primary outcomes were, for patients with recurrent UTIs, subjective (patient‐reported) and objective (positive culture with symptoms) rates of UTI per 12‐month‐equivalent, before versus during treatment. Results: Fifty‐five patients were prescribed intravesical gentamicin, of whom 42 were eligible. Median age was 58 years, and 26 patients (62%) were female. Thirty‐six patients (86%) had neurogenic bladder, and 38 (90%) had pre‐existing catheter use (suprapubic: 17; intermittent: 15; indwelling urethral: six). Median follow‐up was 6 months. Compared with pre‐treatment, patients experienced significantly fewer subjective (median 6.5 vs. 0; p < 0.00001) and objective (median 5.5 vs. 0; p < 0.00001) UTIs per 12‐month‐equivalent. Regarding secondary outcomes, for patients with recurrent UTIs, gentamicin was associated with decreased rates of UTI‐related emergency department presentations per 12‐month‐equivalent (median 1 vs. 0; p = 0.005) and decreased proportion of patients with ≥ 1 multi‐drug‐resistant UTI (70% vs. 23%; p = 0.00002). Median ease‐of‐use was 4/5, and likelihood‐to‐recommend was 5/5. Complications were reported by 11 patients (26%), all Clavien−Dindo Grade I. Of patients with prior catheter blockages, 47% reported decreased catheter blockages, although duration between catheter changes was unchanged (median 28 vs. 28 days; p = 0.53). Conclusions: Intravesical gentamicin appears safe and effective prophylaxis for recurrent UTIs and/or catheter blockages. Trial Registration: This study has been registered with the Australian New Zealand Clinical Trials Registry, submission 389972.


  • Performance of percutaneous core biopsy in predicting renal tumour pathology: a systematic review

    by Rebecca Stokes, Derek Hennessey, Ned Kinnear

    Objectives: To systematically assess the diagnostic accuracy of renal tumour core biopsy for detecting malignancy in adults with localised renal masses. Materials and Methods: A search of the Cochrane, Embase and Medline databases and the grey literature published up to September 2024 was performed using pre‐published methods. Eligible studies were published in English, reported all true‐ and false‐positive and ‐negative results for localised renal tumour core biopsies in unique adult cohorts, and used surgical histology as the reference standard. Studies were excluded if they exclusively reported patients with malignant biopsy or surgical histology. Primary outcomes were biopsy sensitivity and specificity for detecting malignancy. Results: Twenty‐one non‐randomised cohorts were identified, totalling 1735 unique patients. In detecting malignancy, renal tumour core biopsy had a weighted mean sensitivity of 98% (95% confidence interval [CI] 0.96–1.00) and specificity of 94% (95% CI 0.84–1.00). Secondary outcomes were determined, including mean false‐positive rate (6%), false‐negative rate (2%), non‐diagnostic rate on first (8%) and second biopsy attempt (9%), and concordance of tumour sub‐type (92%) and Fuhrmann grade, both exact grade (60%) and simplified low/high grade (79%). Summary receiver‐operating characteristic curve analysis demonstrated high test accuracy (area under the curve 0.97). Risk of bias was moderate to high for most studies. Conclusion: Core biopsy for renal masses in adults has high specificity and sensitivity. Excluding patients for whom biopsy will not change management, near‐routine renal tumour biopsy may reduce rates of nephrectomy for ultimately benign tumours, and optimise operating theatre utilisation.


  • Open Access

    A case report of minimally invasive management of congenital retrocaval ureter

    by Orna T Cantillon, Ibrahim Haidaran, Ned Kinnear, Derek B Hennessey

    Retrocaval ureter (RU) is a rare congenital malformation where the ureteric pathway is altered, passing posteriorly around the inferior vena cava (IVC). Occasionally, this leads to the IVC compressing the ureter, resulting in obstruction. In this report, we discuss a male who presented with severe right-sided flank pain and was otherwise well with no significant medical, urological, or birth history. Initial imaging revealed severe right-sided hydroureter with distinct obstruction point, and likely RU. Anecdotal and small centre cases of acute management and laparoscopic RU repair were reviewed. Initial management focused on pain control requiring a nephrostomy with subsequent transperitoneal laparoscopic dissection and repair. Operative time was 138 min with 50 mL blood loss. Post-operatively the patient recovered well and was symptom free at 6 month follow up ultrasound. Similarly, most reviewed cases chose a trans-peritoneal laparoscopic approach with good outcomes.


  • A systematic review of acquired bladder cancer risk factors

    by Kenneth Patterson, Ned Kinnear, Rory Patterson, Lee Chien Yap, Derek Hennessey

    Background: Bladder cancer remains the ninth most common cancer worldwide. Many of the risk factors associated with bladder cancer are acquired and are therefore modifiable. This study aimed to systematically review the literature to identify the main acquired risk factors associated with the development of bladder cancer. Methods: We performed a meticulous, systematic literature review for relevant studies using two electronic databases PubMed and Medline. Studies deemed eligible examined bladder cancer risk factors and were published in the English language. Results: One hundred and twenty-five full-text articles were included in the review. The majority were case–control studies and cohort studies, with some systematic reviews and meta-analyses included. The acquired risk factors which were most commonly identified include smoking, occupational exposures, dietary factors and medical conditions. Conclusion: Bladder cancer remains a disease with a significant global burden, much of which can be attributable to modifiable and acquired risk factors. A key factor in the primary prevention of bladder cancer is the identification and modification of these risk factors by both physicians and patients. Level of evidence: Not applicable

  • Open Access

    Impact of frozen section on long‐term outcomes in robot‐assisted laparoscopic prostatectomy

    by Ned Kinnear, Paul Cotter Fonseca, Catherine Ogbechie, Sana Adam, Omar Haidar, Aromal Jinaraj, Michael O'CAllaghan, Samita Agarwal, Tim Lane, Nikhil Vasdev, et al.

    Objectives: To compare 1‐year functional and 5‐year oncological outcomes of men undergoing robot‐assisted laparoscopic prostatectomy (RALP) with neurovascular structure‐adjacent frozen‐section examination (NeuroSAFE) with those in men undergoing RALP without NeuroSAFE (standard of care [SOC]). Subjects and Methods: Men undergoing RALP in our centre between 1 January 2009 and 30 June 2018 were enrolled from a prospectively maintained database. Patients were excluded if they had undergone preoperative therapy or postoperative adjuvant therapy or were enrolled in clinical trials. Patients were grouped based on use of NeuroSAFE. Follow‐up was censored at 5 years. The primary outcome was difference in time to biochemical recurrence (BCR) on multivariable analysis, defined as prostate‐specific antigen (PSA) >0.2 ng/L on two consecutive measurements. Secondary outcomes were difference in 1‐year erectile dysfunction and incontinence. Results: In the enrolment period, 1199 consecutive men underwent RALP, of whom 1140 were eligible, including 317 with NeuroSAFE and 823 with SOC. The median PSA follow‐up was 60 months in both groups. Rates of 5‐year BCR were similar on Kaplan–Meier survival curve analysis (11% vs 11%; P = 0.9), as was time to BCR on multivariable Cox proportional hazards modelling (hazard ratio 1.2; P = 0.6). Compared with the SOC group at 1 year, the NeuroSAFE group had similar unadjusted rates of incontinence (5.1% vs 7.7%) and lower unadjusted impotence (57% vs 80%). On multivariable analysis, NeuroSAFE patients had equivalent risk of incontinence (odds ratio [OR] 0.59, 95% CI 0.17–1.6; P = 0.4) but significantly reduced risk of erectile dysfunction (OR 0.37, 95% CI 0.22–0.60; P < 0.001). Conclusions: For men undergoing RALP, compared with SOC, NeuroSAFE patients had equivalent time to BCR and risk of 1‐year incontinence, and significantly lower risk of 1‐year erectile dysfunction.


  • Achieving trifecta outcomes in robotic-assisted partial nephrectomy within a fellowship training centre

    by Ned Kinnear, Anushree Kucheria, Ross Warner, Andrew Brodie, James Adshead

    To assess the robotic-assisted partial nephrectomy (RAPN) trifecta rate within a fellowship program. Patients undergoing RAPN 01/01/2010–01/07/2023 were enrolled from a prospectively maintained database. All cases were performed jointly with surgical fellows, except when privately insured. Patients were excluded if they were converted to open or radical nephrectomy. The primary outcome was achieving the ‘trifecta’ of negative surgical margins, no complications < 30 days post-operatively and warm ischaemia time (WIT) < 25 min. The secondary outcomes were factors associated with trifecta success. Ethics approval was obtained. In the enrolment period, 355 patients underwent intended RAPN, of whom seven were excluded due to conversion to conversion to radical nephrectomy (6 patients) or conversion to open (one). Amongst the 348 eligible patients, median age was 60 years, 115 (33%) were female and 19 were private patients. WIT was < 25 min for 324/337 patients (96%), surgical margins were negative in 325 (93%), 294 (84%) were complication-free at 30 days and 301/320 (94%) had a < 30% decline in estimated glomerular filtration rate at 3–6 months postoperatively. Subsequently, trifecta outcomes were achieved in 253/337 (75%) patients. Comparing with patients without those with trifecta success were similar in all thirteen measured patients and tumour factors. In a teaching hospital, with a fellowship training programme, trifecta outcome is achievable for most RAPN patients, and at a rate comparable to international standards. Fellowship centres should monitor their outcomes to ensure high patient outcomes are maintained alongside training requirements.


  • Concordance between renal tumour biopsy and robotic-assisted partial and radical nephrectomy histology: a 10-year experience

    by Ned Kinnear, Anushree Kucheria, Catherine Ogbechie, Sana Adam, Omar Haidar, Paul Cotter Fonseca, Andrew Brodie, Ben Pullar, James Adshead

    We aimed to assess concordance between renal tumour biopsy (RTB) and surgical pathology from robotic-assisted partial nephrectomy (RAPN) or robotic-assisted radical nephrectomy (RARN). Patients with preoperative RTB undergoing RAPN or RARN for suspected malignancy (9 September 2013–9 September 2023) were enrolled retrospectively from three sites. Patients were excluded if the tumour had prior cryotherapy or if biopsy or nephrectomy histology were unavailable or inconclusive. The primary outcome was concordance with the presence/absence of malignancy. Secondary outcomes were concordance with tumour subtype, World Health Organisation nuclear grade (patients with RTB clear cell or papillary RCC only), false-negative rate, false-positive rate, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). In the enrolment period, 332 and 132 patients underwent RAPN and RARN, respectively. Of these, 160 received preoperative RTB, with nine patients excluded, leaving 151 eligible patients. Median age was 63 years, and 49 (32%) were female. On surgical specimens, 144 patients had malignant histology. RTB was highly concordant with presence/absence of malignancy (147/151, 97%). Concordance with tumour subtype occurred in 141 patients (93%), while concordance with nuclear grade was seen in 42/66 patients (64%, RTB grade missing in 53 patients). False-negative rate, false-positive rate, sensitivity, specificity, PPV, and NPV were 2%, 14%, 98%, 86%, 99%, and 67%, respectively. Limitations include absence of complication data and exclusion of patients biopsied without surgery. In patients undergoing RAPN or RARN, preoperative RTB has high concordance with surgical pathology, both in the presence of malignancy and RCC subtype.


  • Systematic review of the ophthalmic complications of robotic-assisted laparoscopic prostatectomy

    by Joshua Rabinowitz, Ned Kinnear, Michael O’cAllaghan, Derek Hennessey, Fariha Shafi, Andrew Fuller, Mohamed Ibrahim, Timothy Lane, James Adshead, Nikhil Vasdev

    This study aims to review ophthalmic injuries sustained during of robotic-assisted laparoscopic prostatectomy (RALP). A search of Medline, Embase, Cochrane and grey literature was performed using methods registered a priori. Eligible studies were published 01/01/2010–01/05/2023 in English and reported ophthalmic complications in cohorts of > 100 men undergoing RALP. The primary outcome was injury incidence. Secondary outcomes were type and permanency of ophthalmic complications, treatments, risk factors and preventative measures. Nine eligible studies were identified, representing 100,872 men. Six studies reported rates of corneal abrasion and were adequately homogenous for meta-analysis, with a weighted pooled rate of 5 injuries per 1000 procedures (95% confidence interval 3–7). Three studies each reported different outcomes of xerophthalmia, retinal vascular occlusion, and ophthalmic complications unspecified in 8, 5 and 2 men per 1000 procedures respectively. Amongst identified studies, there were no reports of permanent ophthalmic complications. Injury management was poorly reported. No significant risk factors were reported, while one study found African-American ethnicity protective against corneal abrasion (0.4 vs. 3.9 per 1000). Variables proposed (but not proven) to increase risk for corneal abrasion included steep Trendelenburg position, high pneumoperitoneum pressure, prolonged operative time and surgical inexperience. Compared with standard of care, occlusive eyelid dressings (23 vs. 0 per 1000) and foam goggles (20 vs. 1.3 per 1000) were found to reduce rates of corneal abrasion. RALP carries low rates of ophthalmic injury. Urologists should counsel the patient regarding this potential complication and pro-actively implement preventative strategies.